Surgery risk flagged for popular weight-loss, diabetes drugs in new warning
Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy.
The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation.
The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure.
The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned.
The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs.
Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management.
Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN).
All cases were reported with a single suspected medicine according to the TGA.
They have required the product information for each medicine to be updated on the risks.
The full details of the update is found on the TGA website here.
Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy.
The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation.
The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure.
The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned.
The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs.
Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management.
Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN).
All cases were reported with a single suspected medicine according to the TGA.
They have required the product information for each medicine to be updated on the risks.
The full details of the update is found on the TGA website here.
Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy.
The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation.
The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure.
The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned.
The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs.
Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management.
Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN).
All cases were reported with a single suspected medicine according to the TGA.
They have required the product information for each medicine to be updated on the risks.
The full details of the update is found on the TGA website here.
Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy.
The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation.
The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure.
The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned.
The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs.
Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management.
Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN).
All cases were reported with a single suspected medicine according to the TGA.
They have required the product information for each medicine to be updated on the risks.
The full details of the update is found on the TGA website here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
17 hours ago
- Sky News AU
'I can't fit any more in': Dramatically slimmed-down Australian Idol winner Casey Donovan opens up about Ozempic side effects
Casey Donovan has opened up about the surprising side effects of her weight loss medication journey, including feeling "fullness" for the first time in her life. Donovan, 36, recently lost a significant amount of weight after overhauling her lifestyle and using the GLP-1-aided weight loss program Juniper. GLP-1 medications such as Ozempic help regulate appetite and are increasingly being used in medical weight loss programs. On Tuesday, the slimmed-down songstress posted a video via her Instagram account and listed some of the benefits of losing weight. 'My clothing feeling looser and feeling less bloated, not only in my body but also my face,' she wrote. 'Food noise becoming quiet in my mind and feeling freedom with thoughts when it comes to food. 'The feeling of fullness, not really knowing that feeling before this program and now knowing and identifying that feeling and stopping when feeling full and not pushing through as if it were my last meal (I can always have more later of I'm feeling hungry) Learning that I don't need to order the extras.' Donovan also shared her favourite green smoothie recipe after a massive diet and fitness overhaul. The ultra-healthy concoction is made up of cucumber, green apple, celery stick, kale, spinach, plus coconut water and a dash of lemon juice. 'Whiz it all up in your blender and enjoy,' Donovan wrote. While preparing her favourite super smoothie, Donovan elaborated on feeling 'fullness' for the first time thanks to her use of weight loss medication. 'I wanted to talk about some non-scale victories while being on the Juniper program,' she said. 'It's taken me many, many years to understand the satisfaction of what fullness is. 'I can't fit any more in. I physically cannot fit it into my body. 'I've always thought about food (and) how much of it I was going to eat and it occupied a lot of my time (but) now it's just eat for fuel.' Donovan's loyal fans flooded the comment section with support. 'No food noise and eating to fuel sounds amazing,' one fan wrote. 'Will definitely make it! Looks delish,' another user said. Donovan, who recently completed a national tour of Sister Act, first found fame after winning the second season of Australian Idol in 2004, aged just 16. The star is also hoping to start a family with her fiancée Renee Sharples in the 'semi-near future' after recently revealing she was "in such a good place in my life right now".
The Age
a day ago
- The Age
Advocates warned people would die. Now we know someone has
When the former Labor government announced a trial of two fixed pill-testing sites in Queensland in 2024, it included an important provision: an independent evaluation after 12 months. The sites in Bowen Hills and Burleigh Heads opened last year and tested a range of substances – not just recreational drugs such as methamphetamines, cocaine and MDMA, but also commonly prescribed medications, such as Ozempic, valium and ritalin. When the LNP took office, funding for the sites was axed and they closed in April. But the report from the evaluation, conducted by the University of Queensland at a cost to taxpayers of $453,286, is still relevant. The terms of the evaluation were to include an analysis of harm-reduction strategies and the development of a framework to monitor the detection of dangerous substances. The latter point is important. Unlike other states and territories, Queensland doesn't have an overdose monitoring system or a public drug alert network. Loading Several times, the pill-testing service filled this gap, including when it detected nitazenes, extremely potent synthetic opioids that are 40 times more powerful than fentanyl. These analogues are increasingly sold as pain meds, but can quickly become fatal. When the sites closed, Cameron Francis, chief executive of The Loop Australia – the not-for-profit organisation that delivered the pill-testing service – said he feared lives would be lost as a result of the decision. It wasn't an exaggerated warning. In March, Queensland Health issued a clinical alert after protodesnitazene, a type of nitazene, was detected in a toxicology sample. The alert suggested the drug was mistakenly sold as desmetramadol, a medication used to treat chronic pain.
Sydney Morning Herald
a day ago
- Sydney Morning Herald
Advocates warned people would die. Now we know someone has
When the former Labor government announced a trial of two fixed pill-testing sites in Queensland in 2024, it included an important provision: an independent evaluation after 12 months. The sites in Bowen Hills and Burleigh Heads opened last year and tested a range of substances – not just recreational drugs such as methamphetamines, cocaine and MDMA, but also commonly prescribed medications, such as Ozempic, valium and ritalin. When the LNP took office, funding for the sites was axed and they closed in April. But the report from the evaluation, conducted by the University of Queensland at a cost to taxpayers of $453,286, is still relevant. The terms of the evaluation were to include an analysis of harm-reduction strategies and the development of a framework to monitor the detection of dangerous substances. The latter point is important. Unlike other states and territories, Queensland doesn't have an overdose monitoring system or a public drug alert network. Loading Several times, the pill-testing service filled this gap, including when it detected nitazenes, extremely potent synthetic opioids that are 40 times more powerful than fentanyl. These analogues are increasingly sold as pain meds, but can quickly become fatal. When the sites closed, Cameron Francis, chief executive of The Loop Australia – the not-for-profit organisation that delivered the pill-testing service – said he feared lives would be lost as a result of the decision. It wasn't an exaggerated warning. In March, Queensland Health issued a clinical alert after protodesnitazene, a type of nitazene, was detected in a toxicology sample. The alert suggested the drug was mistakenly sold as desmetramadol, a medication used to treat chronic pain.
